Mogrol

Mogrol is a biometabolite of mogrosides, and acts via inhibition of the ERK1/2 and STAT3 pathways, or reducing CREB activation and activating AMPK signaling.

Product Specifications

CAS Number

[88930-15-8]

UNSPSC

12352211

Target

ERK; STAT

Type

Natural Products

Related Pathways

JAK/STAT Signaling; MAPK/ERK Pathway; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Mogrol.html

Purity

99.76

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CC1(C)[C@@H](O)CC[C@@]2([H])[C@]3(C)[C@H](O)C[C@]4(C)[C@@H]([C@H](C)CC[C@@H](O)C(C)(O)C)CC[C@](C)4[C@]3([H])CC=C12

Molecular Formula

C30H52O4

Molecular Weight

476.73

References & Citations

[1]Liu C, et al. Mogrol represents a novel leukemia therapeutic, via ERK and STAT3 inhibition. Am J Cancer Res. 2015 Mar 15;5 (4) :1308-18.|[2]Naoki Harada, et al. Mogrol Derived from Siraitia grosvenorii Mogrosides Suppresses 3T3-L1 Adipocyte Differentiation by Reducing cAMP-Response Element-Binding Protein Phosphorylation and Increasing AMP-Activated Protein Kinase Phosphorylation. PLoS One. 2